4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Hypertrophic Cardiomyopathy by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 124 ongoing clinical trials involving Hypertrophic Cardiomyopathy
Of the 124 trials,47 trials are in Phase II
Furthermore, 39 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Hypertrophic Cardiomyopathy by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Hypertrophic Cardiomyopathy, a Cardiovascular condition. The largest number of ongoing clinical trials for Hypertrophic Cardiomyopathy are conducted in the Asia-Pacific and Europe. North America and Middle East and Africa are among some of the other prominent regions engaged in Hypertrophic Cardiomyopathy-related drug trials.

MyoKardia Inc: The leading ongoing Hypertrophic Cardiomyopathy related clinical trial sponsor

MyoKardia Inc is the top sponsor for Hypertrophic Cardiomyopathy-related ongoing clinical trials.

Bristol-Myers Squibb Co, Newcastle University, Celltrion Inc , and Western Sydney Local Health District (Australia) are among other notable clinical trial sponsors involved in Hypertrophic Cardiomyopathy. AS clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Hypertrophic Cardiomyopathy

Amiodarone Hydrochloride, Amoxicillin trihydrate and Atenolol are among the key marketed drugs involving Hypertrophic Cardiomyopathy.

Amiodarone Hydrochloride is an antiarrhythmic agent. It functions via Alpha 1 Adrenergic Receptor (ADRA1) Antagonist; Beta 1 Adrenergic Receptor (Beta 1 Adrenoreceptor or ADRB1) Antagonist; Calcium Channel Blocker; Potassium Channel (KCN) Blocker; Sodium Channel Blocker mechanism of action. Amiodarone Hydrochloride is formulated as tablets for oral route of administration. Amiodarone Hydrochloride is indicated for the treatment ventricular fibrillation, ventricular tachycardia, heart failure, atrial fibrillation associated with low cardiac function and hypertrophic cardiomyopathy. Amiodarone Hydrochloride was first approved in 2009 and is marketed in Japan by Toa Eiyo Ltd.

Amoxicillin trihydrate is a broad-spectrum semisynthetic antibiotic, acts as an antibacterial agent. It functions via Penicillin Binding Protein (PBP) Inhibitor mechanism of action. Amoxicillin trihydrate is formulated as capsules and powder for suspension for oral route of administration. Amoxicillin trihydrate was first approved in 2019 and is marketed solely in Canada by Pro-Doc Ltee.